• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

mBio . Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae

tetano

Editor, Senior Moderator
mBio


. 2021 Sep 7;e0159921.
doi: 10.1128/mBio.01599-21. Online ahead of print.
Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae


Jianghua Wu[SUP] #[/SUP][SUP] 1 2 [/SUP], Lu Tang[SUP] #[/SUP][SUP] 1 2 [/SUP], Yanling Ma[SUP] #[/SUP][SUP] 3 [/SUP], Yu Li[SUP] #[/SUP][SUP] 3 [/SUP], Dongmei Zhang[SUP] 3 [/SUP], Qian Li[SUP] 1 2 [/SUP], Heng Mei[SUP] 1 2 [/SUP], Yu Hu[SUP] 1 2 [/SUP]



Affiliations

Abstract

Cellular immunity may be involved in organ damage and rehabilitation in patients with coronavirus disease 2019 (COVID-19). We aimed to delineate immunological features of COVID-19 patients with pulmonary sequelae (PS) 1 year after discharge. Fifty COVID-19 survivors were recruited and classified according to radiological characteristics, including 24 patients with PS and 26 patients without PS. Phenotypic and functional characteristics of immune cells were evaluated by multiparametric flow cytometry. Patients with PS had an increased proportion of natural killer (NK) cells and a lower percentage of B cells than patients without PS. Phenotypic and functional features of T cells in patients with PS were predominated by the accumulation of CD4-positive (CD4[SUP]+[/SUP]) T cells secreting interleukin 17A (IL-17A), short-lived effector-like CD8[SUP]+[/SUP] T cells (CD27-negative [CD27[SUP]-[/SUP]] CD62L[SUP]-[/SUP]), and senescent T cells with excessive secretion of granzyme B/perforin/interferon gamma (IFN-γ). NK cells were characterized by the excessive secretion of granzyme B and perforin and the downregulation of NKP30 and NKP46; highly activated NKT and γδ T cells exhibited NKP30 and TIM-3 upregulation and NKB1 downregulation in patients with PS. However, immunosuppressive cells were comparable between the two groups. The interrelationship of immune cells in COVID-19 was intrinsically identified, whereby T cells secreting IL-2, IL-4, and IL-17A were enriched among CD28[SUP]+[/SUP] and CD57[SUP]-[/SUP] cells and cells secreting perforin/granzyme B/IFN-γ/tumor necrosis factor alpha (TNF-α)-expressed markers of terminal differentiation. CD57[SUP]+[/SUP] NK cells, CD4[SUP]+[/SUP]Perforin[SUP]+[/SUP] T cells, and CD8[SUP]+[/SUP] CD27[SUP]+[/SUP] CD62L[SUP]+[/SUP] T cells were identified as the independent predictors for residual lesions. Overall, our findings unveil the profound imbalance of immune landscape that may correlate with organ damage and rehabilitation in COVID-19. IMPORTANCE A considerable proportion of COVID-19 survivors have residual lung lesions such as ground-glass opacity and fiber streak shadow. To determine the relationship between host immunity and residual lung lesions, we performed an extensive analysis of immune responses in convalescent patients with COVID-19 1 year after discharge. We found significant differences in immunological characteristics between patients with pulmonary sequelae and patients without pulmonary sequelae 1 year after discharge. Our study highlights the profound imbalance of immune landscape in the COVID-19 patients with pulmonary sequelae, characterized by the robust activation of cytotoxic T cells, NK cells, and γδ T cells, as well as the deficiencies of immunosuppressive cells. Importantly, CD57[SUP]+[/SUP] NK cells, CD4[SUP]+[/SUP]Perforin[SUP]+[/SUP] T cells, and CD8[SUP]+[/SUP] CD27[SUP]+[/SUP] CD62L[SUP]+[/SUP] T cells were identified as the independent predictors for residual lesions.

Keywords: COVID-19; cellular immunity; pulmonary sequelae.
 
Back
Top Bottom